{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T05:49:32Z","timestamp":1715752172402},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Leipzig"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Die mittelschwere bis schwere Psoriasis vulgaris kann wirksam mit immunmodulierenden Biologika wie dem Interleukin-17A-Inhibitor Secukinumab behandelt werden. In der Praxis stellt sich jedoch oft die Frage nach dem Vorgehen in besonderen Situationen, beispielsweise bei Infektionen, Komorbidit\u00e4t, Schwangerschaft oder operativen Eingriffen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ziel der Arbeit<\/jats:title>\n                <jats:p>In diesem Konsensdokument deutscher Psoriasisexperten sollen in Erg\u00e4nzung zu den aktuellen Leitlinien h\u00e4ufige Fragen aus dem Therapiealltag zur Behandlung der Psoriasis mit Secukinumab beantwortet werden.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methoden<\/jats:title>\n                <jats:p>In einem virtuellen Expertentreffen im Mai 2020 wurden auf Grundlage von Erfahrungen der Teilnehmer und aktueller Literatur praxisrelevante Aspekte der Behandlung der Psoriasis er\u00f6rtert. Darauf basierend wurde ein Konsensdokument verfasst.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Die vorliegende Arbeit bietet praktische Hinweise zur Anamnese einschlie\u00dflich der Erfassung von Vortherapien, Schweregrad der Psoriasis und Begleiterkrankungen vor Beginn einer Therapie mit Secukinumab. Ferner wird auf das Vorgehen bei Impfungen, Infektionen, operativen Eingriffen, Sondermanifestationen der Psoriasis und Komorbidit\u00e4ten einschlie\u00dflich vorbestehenden Autoimmunerkrankungen und Tumorerkrankungen unter Therapie mit Secukinumab eingegangen. Auch Fragen zur Familienplanung und zu gesundheitspolitischen Regularien werden diskutiert.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>Die in diesem Konsensdokument zusammengefassten unterst\u00fctzenden Empfehlungen zur Behandlung der Psoriasis mit Secukinumab sollen dazu beitragen, f\u00fcr die Patienten eine optimale Therapie zu erreichen und ihre Lebensqualit\u00e4t zu verbessern.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00105-021-04871-9","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T12:04:24Z","timestamp":1629461064000},"page":"984-991","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Behandlung der Psoriasis mit Secukinumab"],"prefix":"10.1007","volume":"72","author":[{"given":"Andreas","family":"K\u00f6rber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha","family":"Gerdes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"von Kiedrowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Knut","family":"Sch\u00e4kel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sticherling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Wilsmann-Theis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Wohlrab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Christoph","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"4871_CR1","first-page":"3","volume":"4","author":"M Augustin","year":"2017","unstructured":"Augustin\u00a0M, Enk\u00a0A, von Kiedrowski\u00a0R et\u00a0al (2017) Einsatz von Systemtherapeutika und Biologika in der leitliniengerechten Therapie der mittelschweren bis schweren Psoriasis vulgaris. Psonet Mag 4:3\u201327","journal-title":"Psonet Mag"},{"key":"4871_CR2","unstructured":"Augustin\u00a0M, von Kiedrowski\u00a0R, K\u00f6rber\u00a0A et al (2020) Verfahrensweise beider Systemtherapie von Patienten mit Psoriasis w\u00e4hrend der pandemischen Phase von SARS-CoV-2(Coronavirus). PsoNet"},{"key":"4871_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jaad.2017.05.033","volume":"77","author":"J Bagel","year":"2017","unstructured":"Bagel\u00a0J, Duffin\u00a0KC, Moore\u00a0A et al (2017) The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a\u00a024-week, randomized, double-blind, placebo-controlled phase 3b study. J\u00a0Am Acad Dermatol 77:667\u2013674","journal-title":"J Am Acad Dermatol"},{"key":"4871_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/jdv.12997","volume":"30","author":"W Bakkour","year":"2016","unstructured":"Bakkour\u00a0W, Purssell\u00a0H, Chinoy\u00a0H et al (2016) The risk of post-operative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures. J\u00a0Eur Acad Dermatol Venereol 30:86\u201391","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4871_CR5","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1128\/CVI.00386-12","volume":"19","author":"A Chioato","year":"2012","unstructured":"Chioato\u00a0A, Noseda\u00a0E, Stevens\u00a0M et al (2012) Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study. Clin Vaccine Immunol 19:1597\u20131602","journal-title":"Clin Vaccine Immunol"},{"key":"4871_CR6","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jaad.2016.06.014","volume":"75","author":"YM Choi","year":"2016","unstructured":"Choi\u00a0YM, Debbaneh\u00a0M, Weinberg\u00a0JM et\u00a0al (2016) From the medical board of the national psoriasis foundation: perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. J\u00a0Am Acad Dermatol 75:798\u2013805.e7","journal-title":"J Am Acad Dermatol"},{"key":"4871_CR7","first-page":"718","volume":"79","author":"A Deodhar","year":"2020","unstructured":"Deodhar\u00a0A, Mcinnes\u00a0I, Baraliakos\u00a0X et\u00a0al (2020) Secukinumab demonstrates a\u00a0consistent safety profile in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis over long term: Updated pooled safety analyses. Ann Rheum Dis 79:718","journal-title":"Ann Rheum Dis"},{"key":"4871_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"A Deodhar","year":"2019","unstructured":"Deodhar\u00a0A, Mease\u00a0PJ, Mcinnes\u00a0IB et al (2019) Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther 21:111","journal-title":"Arthritis Res Ther"},{"key":"4871_CR9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/cvr\/cvz009","volume":"115","author":"YA Elnabawi","year":"2019","unstructured":"Elnabawi\u00a0YA, Dey\u00a0AK, Goyal\u00a0A et\u00a0al (2019) Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a\u00a0prospective observational study. Cardiovasc Res 115:721\u2013728","journal-title":"Cardiovasc Res"},{"key":"4871_CR10","unstructured":"Fachinformation Secukinumab, Stand Dezember 2020"},{"key":"4871_CR11","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.vaccine.2019.10.081","volume":"38","author":"V Furer","year":"2020","unstructured":"Furer\u00a0V, Zisman\u00a0D, Kaufman\u00a0I et\u00a0al (2020) Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab. Vaccine 38:847\u2013851","journal-title":"Vaccine"},{"key":"4871_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2016.07.058","volume":"76","author":"A Gottlieb","year":"2017","unstructured":"Gottlieb\u00a0A, Sullivan\u00a0J, Van Doorn\u00a0M et\u00a0al (2017) Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a\u00a0randomized controlled trial. J\u00a0Am Acad Dermatol 76:70\u201380","journal-title":"J Am Acad Dermatol"},{"key":"4871_CR13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/bjd.18331","volume":"182","author":"AB Gottlieb","year":"2020","unstructured":"Gottlieb\u00a0AB, Kubanov\u00a0A, Van Doorn\u00a0M et al (2020) Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2\u00b75-year results from GESTURE, a\u00a0randomized, double-blind, placebo-controlled trial. Br J Dermatol 182:889\u2013899","journal-title":"Br J Dermatol"},{"key":"4871_CR14","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/1346-8138.13306","volume":"43","author":"S Imafuku","year":"2016","unstructured":"Imafuku\u00a0S, Honma\u00a0M, Okubo\u00a0Y et al (2016) Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J\u00a0Dermatol 43:1011\u20131017","journal-title":"J Dermatol"},{"key":"4871_CR15","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","volume":"395","author":"IB Mcinnes","year":"2020","unstructured":"Mcinnes\u00a0IB, Behrens\u00a0F, Mease\u00a0PJ et al (2020) Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a\u00a0double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet 395:1496\u20131505","journal-title":"Lancet"},{"key":"4871_CR16","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaad.2019.01.066","volume":"80","author":"U Mrowietz","year":"2019","unstructured":"Mrowietz\u00a0U, Bachelez\u00a0H, Burden\u00a0AD et al (2019) Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J\u00a0Am Acad Dermatol 80:1344\u20131352","journal-title":"J Am Acad Dermatol"},{"key":"4871_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz\u00a0U, Kragballe\u00a0K, Reich\u00a0K et\u00a0al (2011) Definition of treatment goals for moderate to severe psoriasis: a\u00a0European consensus. Arch Dermatol Res 303:1\u201310","journal-title":"Arch Dermatol Res"},{"key":"4871_CR18","doi-asserted-by":"crossref","unstructured":"Nast\u00a0A, Altenburg\u00a0A, Augustin\u00a0M et al (2021) Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm. J\u00a0Dtsch Dermatol Ges (in print)","DOI":"10.1111\/ddg.14508_g"},{"key":"4871_CR19","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1111\/jdv.14454","volume":"31","author":"A Nast","year":"2017","unstructured":"Nast\u00a0A, Spuls\u00a0PI, van der Kraaij\u00a0G et al (2017) European S3-Guideline on the systemic treatment of psoriasis vulgaris\u2014update apremilast and secukinumab\u2014EDF in cooperation with EADV and IPC. J\u00a0Eur Acad Dermatol Venereol 31:1951\u20131963","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4871_CR20","first-page":"674","volume":"13","author":"MA Radtke","year":"2015","unstructured":"Radtke\u00a0MA, Mrowietz\u00a0U, Feuerhahn\u00a0J et\u00a0al (2015) Fr\u00fcherkennung der Komorbidit\u00e4t bei Psoriasis: Konsensusempfehlungen der Nationalen Konferenz zur Versorgung der Psoriasis. J\u00a0Dtsch Dermatol Ges 13:674\u2013690","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"4871_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19262","author":"K Reich","year":"2020","unstructured":"Reich\u00a0K, Sullivan\u00a0J, Arenberger\u00a0P et al (2020) Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.19262","journal-title":"Br J Dermatol"},{"key":"4871_CR22","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/bjd.17351","volume":"181","author":"K Reich","year":"2019","unstructured":"Reich\u00a0K, Sullivan\u00a0J, Arenberger\u00a0P et al (2019) Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol 181:954\u2013966","journal-title":"Br J Dermatol"},{"key":"4871_CR23","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1111\/ced.13751","volume":"44","author":"L Sacchelli","year":"2019","unstructured":"Sacchelli\u00a0L, Patrizi\u00a0A, Loi\u00a0C et al (2019) Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis. Clin Exp Dermatol 44:e243\u2013e244","journal-title":"Clin Exp Dermatol"},{"key":"4871_CR24","volume-title":"S2k Leitlinie: Tuberkulose im Erwachsenenalter","author":"T Schaberg","year":"2017","unstructured":"Schaberg\u00a0T, Bauer\u00a0T, Brinkmann\u00a0F et\u00a0al (2017) S2k Leitlinie: Tuberkulose im Erwachsenenalter"},{"key":"4871_CR25","first-page":"1","volume":"34","author":"St\u00e4ndige Impfkommission","year":"2020","unstructured":"St\u00e4ndige Impfkommission (2020) Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut 2020\/2021. Epidemiol Bull 34:1\u201368","journal-title":"Epidemiol Bull"},{"key":"4871_CR26","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","volume":"156","author":"S Vaengebjerg","year":"2020","unstructured":"Vaengebjerg\u00a0S, Skov\u00a0L, Egeberg\u00a0A et al (2020) Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol 156:421\u2013429","journal-title":"JAMA Dermatol"},{"issue":"Suppl","key":"4871_CR27","first-page":"1","volume":"09","author":"R Von Kiedrowski","year":"2019","unstructured":"Von Kiedrowski\u00a0R, Dirschka\u00a0T, Kurzen\u00a0H et\u00a0al (2019) Empfehlungen f\u00fcr die ambulante Versorgung von Psoriasis vulgaris \u2013 Aktualisierter praxisnaher Behandlungspfad. Dermatologe 09(Suppl):1\u201324","journal-title":"Dermatologe"},{"key":"4871_CR28","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.3389\/fimmu.2019.03096","volume":"10","author":"E Von Stebut","year":"2019","unstructured":"Von Stebut\u00a0E, Boehncke\u00a0WH, Ghoreschi\u00a0K et al (2019) IL-17A in psoriasis and beyond: cardiovascular and metabolic implications. Front Immunol 10:3096","journal-title":"Front Immunol"},{"key":"4871_CR29","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","volume":"139","author":"E Von Stebut","year":"2019","unstructured":"Von Stebut\u00a0E, Reich\u00a0K, Tha\u00e7i\u00a0D et\u00a0al (2019) Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52\u00a0weeks. J\u00a0Invest Dermatol 139:1054\u20131062","journal-title":"J Invest Dermatol"},{"key":"4871_CR30","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00103-019-02905-1","volume":"62","author":"N Wagner","year":"2019","unstructured":"Wagner\u00a0N, Assmus\u00a0F, Arendt\u00a0G et al (2019) Impfen bei Immundefizienz. Anwendungshinweise zu den von der St\u00e4ndigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entz\u00fcndlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 62:494\u2013515","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"4871_CR31","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1111\/bjd.16901","volume":"179","author":"RB Warren","year":"2018","unstructured":"Warren\u00a0RB, Reich\u00a0K, Langley\u00a0RG et\u00a0al (2018) Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Br J Dermatol 179:1205\u20131207","journal-title":"Br J Dermatol"},{"key":"4871_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00403-013-1318-9","volume":"305","author":"J Wohlrab","year":"2013","unstructured":"Wohlrab\u00a0J, Fiedler\u00a0G, Gerdes\u00a0S et\u00a0al (2013) Recommendations for detection of individual risk for comorbidities in patients with psoriasis. Arch Dermatol Res 305:91\u201398","journal-title":"Arch Dermatol Res"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04871-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-021-04871-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04871-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T16:46:40Z","timestamp":1634921200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-021-04871-9"}},"subtitle":["Praxisrelevante Hinweise"],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["4871"],"URL":"https:\/\/doi.org\/10.1007\/s00105-021-04871-9","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]},"assertion":[{"value":"7 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0K\u00f6rber<b>:<\/b> Berater, Redner oder Teilnahme an klinischen Studien gesponsert durch AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim Pharma, Bristol Myers Squibb, Celgene, Janssen-Cilag, Leo Pharma, Lilly, Merck Sharp & Dohme Corp., Novartis, Pfizer und UCB. M.\u00a0Augustin<b>:<\/b> Berater, Redner oder Teilnahme an klinischen Studien gesponsert durch Abbott\/AbbVie, ALK Scherax, Almirall, Amgen, Beiersdorf, Biogen Idec, BMS, Boehringer Ingelheim, Celgene, Centocor, Dermira, Eli Lilly, Forward Pharma, Fresenius, Galderma, GSK, Hexal, Incyte, Janssen-Cilag, LEO Pharma, Lilly, Medac, Menlo, Merck, MSD, Mylan, Novartis, Pfizer, Regeneron, Sandoz, Sanofi-Aventis, Stallergenes, Stiefel, Teva, TK, Trevi, UCB und Xenoport. F.\u00a0Behrens: Forschungsf\u00f6rderung durch: Pfizer, Janssen, Chugai, Celgene und Roche; Berater und Referentenhonorar von: Pfizer, AbbVie, Sanofi, Lilly, Novartis, Genzyme, Boehringer, Janssen, MSD, Celgene, Roche, Chugai, BMS und UCB Pharma. S.\u00a0Gerdes<b>:<\/b> Berater, Redner oder Teilnahme an klinischen Studien gesponsert durch AbbVie, Affibody AB, Akari Therapeutics Plc, Almirall-Hermal, Amgen, AnaptysBio, Argenx BV, AstraZeneca, Biogen Idec, Bioskin, Bristol-Myers Squibb, Boehringer-Ingelheim, Celgene, Centocor, Dermira, Eli Lilly, Foamix, Forward Pharma, Galderma, Hexal AG, Incyte Inc., Janssen-Cilag, Johnson & Johnson, Kymab, Leo Pharma, Medac, MSD, Neubourg Skin Care GmbH, Novartis, Pfizer, Principia Biopharma, Regeneron, Sandoz, Sanofi-Aventis, Sienna Biopharmaceuticals, Takeda, Trevi Therapeutics, UCB und Vascular Biogenics. R.\u00a0von Kiedrowski<b>: <\/b>Erbringt durch seine Dienstleistungsfirma CMS<sup>3<\/sup> GmbH Beratungsleistungen, Registerforschung, T\u00e4tigkeiten als Pr\u00fcfarzt bei interventionellen und nichtinterventionellen Studien, sonstige Dienstleistungen und wissenschaftliche Vortr\u00e4ge f\u00fcr AbbVie, ALK Scherax, Almirall Hermal, Beiersdorf Dermo Medical, Biofrontera, Biogen, BMS, Boehringer Ingelheim, Celgene, Dermapharm, Foamix, Gilead, Hexal, Janssen-Cilag, Leo, Lilly, Meda, Medac, Menlo, MSD, Novartis, Dr. R.\u00a0Pfleger, Pfizer, Regeneron, Sanofi, Stallergenes, Stiefel GSK, Tigercut und UCB. K.\u00a0Sch\u00e4kel<b>: <\/b>Berater, Redner oder Teilnahme an klinischen Studien gesponsert durch AbbVie, Amgen, Almirall, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chugai, Galderma, Janssen-Cilag, LEO Pharma, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Polichem, Regeneron und UCB. M.\u00a0Sticherling<b>:<\/b> Berater, Redner oder Teilnahme an klinischen Studien gesponsert durch Abbott\/AbbVie, Almirall-Hermal, Amgen, Biogen Idec, Bioskin, Boehringer-Ingelheim, Celgene, Centocor, Eli Lilly, Galderma, Hexal AG, Incyte Inc., Janssen-Cilag, Johnson & Johnson, Leo Pharma, Merck Serono, MSD, Novartis, Pfizer, Principia Biopharma, Regeneron, Sandoz, Sanofi-Aventis, Schering-Plough, Taked und UCB. D.\u00a0Wilsmann-Theis<b>:<\/b> Berater, Redner oder Teilnahme an klinischen Studien gesponsert durch AbbVie, Almirall, Amgen, Anaptys, Biogen, Boehringer Ingelheim Pharma, Bristol Myers Squibb, Celgene, Forward Pharma, GlaxoSmithKline, Janssen-Cilag, Leo, Lilly, Medac, Merck Sharp & Dohme Corp., Novartis, Pfizer, UCB und VBL. J.\u00a0Wohlrab<b>:<\/b> Berater, Redner, Forschungsf\u00f6rderung oder Teilnahme an klinischen Studien gesponsert durch AbbVie, Almirall, Amgen, Biogen, Celgene, Galderma, GSK, Hexal, Janssen-Cilag, Leo, Lilly, MSD, Medac, Mylan, Novartis, Pfizer, Sanofi und UCB. J.-C.\u00a0Simon<b>:<\/b> Berater, Redner oder Teilnahme an klinischen Studien gesponsert durch AbbVie, Amgen, Almirall, Bristol-Myers Squibb, Celgene, Galderma, Janssen-Cilag, LEO Pharma, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron und UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}